Search

1 to 10 of 179
Sort by

Library Entry
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

Nivolumab combined with ipilimumab have shown activity in melanoma brain metastasis (MBM). However, in most of the clinical trials investigating immunotherapy in this subgroup, patients with symptomatic MBM and/or prior local brain radiotherapy were excluded. The authors studied the efficacy of...



Library Entry
Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma

Metastatic sarcomatoid renal cell carcinoma (sRCC) is an aggressive variant of RCC with generally poor prognosis. Treatment with vascular endothelial growth factor inhibitors or chemotherapy generates only short-lived responses. Recent research has suggested a role for combination checkpoint...



Library Entry
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

Deciphering the correlation between immune-related adverse events (irAEs) categorized by organ system class and clinical benefit of immunotherapy is critical for clinical practice. The aim of this study was to investigate the incidence rates of irAEs and their correlations with objective...


Library Entry
Dual checkpoint inhibitor-associated eosinophilic enteritis

Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events. The authors report a case of dual checkpoint inhibitor-associated hypereosinophilia and...


Library Entry
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma

Immune checkpoint inhibitors have improved clinical outcomes including survival in several malignancies but have also been associated with a range of immune-related adverse events (irAEs). Neurological irAEs are rare compared to the more typical skin, gastrointestinal, and endocrine toxicities,...


Library Entry
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis

Hypophysitis is a well-recognized immune-related adverse event in patients treated with immune checkpoint inhibitors for cancer. Some anterior pituitary hormones may recover; however, secondary adrenal insufficiency is usually permanent. This case documents an unusual recovery from secondary...



Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2019

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally...